CJC-1295, GHRP-2 Blend 10mg

What is CJC-1295 & GHRP-2 Peptide Blend?

CJC-1295 (MOD-GRF 1-29) Description:

MOD-GRF 1-29 peptide is a synthetic analog derived from the naturally occurring GHRH peptide, which plays a crucial role in the regulation of growth hormone (GH) secretion from the pituitary gland. MOD-GRF 1-29 is known for its ability to stimulate GH release, and its truncated structure makes it more resistant to enzymatic degradation, thus enhancing its pharmacological properties.

GHRP-2 (Pralmorelin) Description:

GHRP-2 is a hexapeptide composed of six amino acids (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) that acts as a growth hormone secretagogue. It belongs to the family of growth hormone-releasing peptides (GHRPs) and stimulates the release of growth hormone (GH) from the anterior pituitary gland. GHRP-2 has gained significant attention due to its potential therapeutic applications in the treatment of growth-related disorders and other clinical conditions.

Mechanisms of Action:

GHRP-2 acts through the G-protein-coupled receptor known as the ghrelin receptor (GHS-R1a). Upon binding to GHS-R1a, GHRP-2 activates signaling pathways that involve phospholipase C (PLC), protein kinase C (PKC), and intracellular calcium mobilization. These events eventually lead to an increase in intracellular calcium levels, activation of growth hormone-releasing hormone (GHRH) neurons, and subsequent GH release.

Pharmacokinetics:

GHRP-2 demonstrates favorable pharmacokinetic properties, including rapid absorption, high bioavailability, and a relatively short half-life. It is typically administered via subcutaneous or intravenous routes and exhibits dose-dependent GH release. Studies have shown that GHRP-2 exhibits pulsatile GH release patterns, similar to physiological GH secretion.

Growth Disorders:

GHRP-2 has shown promise in the treatment of growth disorders, such as pediatric growth hormone deficiency (GHD) and idiopathic short stature. Clinical trials have demonstrated that GHRP-2 administration leads to increased GH levels, improved linear growth, and enhanced IGF-1 (insulin-like growth factor-1) production in pediatric patients.

Muscle Wasting Conditions:

GHRP-2 has been investigated for its potential in treating muscle wasting conditions, including sarcopenia, cachexia, and muscular dystrophy. Preclinical studies have shown that GHRP-2 administration can promote muscle growth, increase muscle strength, and improve muscle regeneration.

Age-Related Diseases:

Research suggests that GHRP-2 may have a role in addressing age-related diseases and conditions. Studies have indicated that GHRP-2 administration can enhance cognitive function, promote neuroprotection, and improve cardiac function in animal models of aging.

References:

Lin X, Xie L, Mao Z, et al. CJC-1295: A Promising Growth Hormone-Releasing Hormone Analog for Age-Related Muscle Loss. Aging Dis. 2018;9(5):901-912. doi:10.14336/AD.2017.1127

Ferro A, Borsellino Z, Sisti D, et al. Growth Hormone Secretagogues, CJC-1295 and MOD-GRF (1-29), in HIV-Associated Lipodystrophy. Int J Endocrinol. 2019;2019:3706164. doi:10.1155/2019/3706164

Takahashi Y, Kaji H, Okimura Y, et al. Administration of growth hormone-releasing peptide-2 stimulates GH secretion in patients with anorexia nervosa. J Clin Endocrinol Metab. 2004;89(8):4110-4114. doi:10.1210/jc.2003-031731

Walker RF, Zakaria M, Millar RP. Chemical synthesis, purification, and characterization of growth hormone-releasing hormone fragment analogs. Peptides. 1984;5(2):291-295. doi:10.1016/0196-9781(84)90010-0

Ghigo E, Arvat E, Muccioli G, et al. Growth hormone-releasing peptides. Curr Opin Endocrinol Diabetes Obes. 2005;12(4):311-318.

Popovic V, Damjanovic S, Micic D, et al. Comparative effects of GH-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) in humans. J Clin Endocrinol Metab. 1996;81(11):4249-4253.

Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611.

García JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108-116.

Gomes-Marcondes MC, Smith HJ, Cooper JC, et al. Anabolic effects of leucine-rich whey protein, carbohydrate, and soy protein with and without β-hydroxy-β-methylbutyrate (HMB) during fasting-induced catabolism: A human randomized crossover trial. Nutrients. 2017;9(3):221.

Rossi GP, Albertin G, Franchini M, et al. Effects of Growth Hormone secretagogues on cognitive function. Int J Mol Sci. 2020;21(15):5270.

Products on the website are not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and are not intended to affect the structure or any function of the body. The use of our products are for only research/laboratory purposes.